A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma

Anti-cancer Drugs
Jen-Shi ChenCarlos Linn

Abstract

This phase I/II study was conducted to determine the maximum recommended dose of pemetrexed when given in combination with a fixed dose of cisplatin, and the efficacy, toxicity and association of 5,10-methylenetetrahydrofolate reductase (MTHFR) variants with this pemetrexed--cisplatin combination, in patients with unresectable, advanced gastric carcinoma. Patients 18-70 years of age, with stage IV disease or post-surgery recurrence, no earlier palliative chemotherapy, 0 or 1 Eastern Cooperative Oncology Group performance status, were included. The cisplatin dose was 75 mg/m. In phase I, the initial dose of pemetrexed was 600 mg/m, escalated in 100 mg/m increments. In phase II, efficacy, including overall response rate, overall survival, as well as toxicity and MTHFR pharmacogenetics were investigated. Phase I enrolled 16 patients; 700 mg/m was defined as pemetrexed recommended dose. Thirteen serious adverse events were reported; the most common grade 3/4 toxicities were haematologic (10 of 13, 76.9%). Phase II enrolled 73 patients, 69 qualified for safety and 68 for efficacy analysis; 65 for pharmacogenomic analysis. Overall response rate was 23.5% (14.1%, 35.4%), disease control rate 55.9%, median overall survival 11.8 months ...Continue Reading

References

Oct 28, 1998·Proceedings of the National Academy of Sciences of the United States of America·P J Bagley, J Selhub
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N BokuI Hyodo
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R S Go, A A Adjei
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R ThödtmannA R Hanauske
Jun 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S R AlbertsC J H van de Velde
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicholas J VogelzangPaolo Paoletti
Sep 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E BajettaW John
Nov 3, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S S WöhrerM Hejna
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
Jun 17, 2005·Cancer Science·Jee Hyun KimYung-Jue Bang
Feb 21, 2006·World Journal of Gastroenterology : WJG·Ryan Swan, Thomas J Miner
Apr 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Annamaria RuzzoMauro Magnani
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Farin KamangarWilliam F Anderson
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anna D WagnerWolfgang E Fleig
Jun 21, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xifeng WuJaffer A Ajani
Nov 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemUNKNOWN V325 Study Group
Dec 22, 2007·Cell Biochemistry and Function·Renfang MaoSongbin Fu
Jan 4, 2008·The New England Journal of Medicine·David CunninghamUNKNOWN Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom
Mar 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Salah-Eddin Al-BatranUNKNOWN Arbeitsgemeinschaft Internistische Onkologie
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio Vittorio ScagliottiDavid Gandara
Jan 16, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Elena De Mattia, Giuseppe Toffoli
Feb 12, 2009·The Journal of Rheumatology·Mark C Fisher, Bruce N Cronstein
Feb 17, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L CelioE Bajetta

❮ Previous
Next ❯

Citations

Sep 4, 2012·Journal of Medical Case Reports·Takashi SatoYoshiaki Ishigatsubo
Sep 18, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Hai LanYan Li

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.